Tokyo Tape
Sign in
← Terumo

Quarterly report · Q3

4543.TEDINET S100SSIE
Period2023-04-01 → 2023-12-31
Filed2024-02-09
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥683.0bn2023-04-01 → 2023-12-31Cons.Revenue IFRS
Revenue¥239.1bn2023-10-01 → 2023-12-31dCons.Revenue IFRS
Revenue¥820.2bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥618.0bn2022-04-01 → 2022-12-31Cons.Revenue IFRS
Revenue¥214.7bn2022-10-01 → 2022-12-31dCons.Revenue IFRS
Operating income¥105.5bn2023-04-01 → 2023-12-31Cons.Operating profit loss IFRS
Operating income¥39.0bn2023-10-01 → 2023-12-31dCons.Operating profit loss IFRS
Operating income¥93.5bn2022-04-01 → 2022-12-31Cons.Operating profit loss IFRS
Operating income¥37.5bn2022-10-01 → 2022-12-31dCons.Operating profit loss IFRS
Profit before tax¥105.7bn2023-04-01 → 2023-12-31Cons.Profit loss before tax IFRS
Profit before tax¥39.3bn2023-10-01 → 2023-12-31dCons.Profit loss before tax IFRS
Profit before tax¥116.1bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥92.1bn2022-04-01 → 2022-12-31Cons.Profit loss before tax IFRS
Profit before tax¥37.5bn2022-10-01 → 2022-12-31dCons.Profit loss before tax IFRS
Net income (owners)¥79.9bn2023-04-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥29.8bn2023-10-01 → 2023-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥89.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥70.2bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥29.9bn2022-10-01 → 2022-12-31dCons.Profit loss attributable to owners of parent IFRS
Net income¥79.9bn2023-04-01 → 2023-12-31Cons.Profit loss IFRS
Net income¥29.8bn2023-10-01 → 2023-12-31dCons.Profit loss IFRS
Net income¥70.2bn2022-04-01 → 2022-12-31Cons.Profit loss IFRS
Net income¥29.9bn2022-10-01 → 2022-12-31dCons.Profit loss IFRS
Total assets¥1.69Tat 2023-12-31Cons.Assets IFRS
Total assets¥1.60Tat 2023-03-31Cons.Assets IFRS
Total assets¥1.54Tat 2022-12-31Cons.Total assets IFRS (5-year summary)
Total liabilities¥475.7bnat 2023-12-31Cons.Liabilities IFRS
Total liabilities¥491.2bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥1.22Tat 2023-12-31Cons.Equity IFRS
Net assets / equity¥1.11Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥1.07Tat 2022-12-31Cons.Equity IFRS
Net assets / equity¥1.01Tat 2022-03-31dCons.Equity IFRS
Equity (owners)¥1.22Tat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.11Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.07Tat 2022-12-31Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥163.6bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥187.3bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥162.4bnat 2022-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥205.3bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥91.2bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥117.5bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥74.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥53.1bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥59.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥41.9bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥68.7bn2023-04-01 → 2023-12-31Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥86.6bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥84.5bn2022-04-01 → 2022-12-31Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥107.332023-04-01 → 2023-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥40.062023-10-01 → 2023-12-31dCons.Basic earnings loss per share IFRS
EPS (basic)¥1192022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥93.252022-04-01 → 2022-12-31Cons.Basic earnings loss per share IFRS
EPS (basic)¥39.972022-10-01 → 2022-12-31dCons.Basic earnings loss per share IFRS
EPS (diluted)¥107.292023-04-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥40.052023-10-01 → 2023-12-31dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥118.952022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥93.212022-04-01 → 2022-12-31Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥39.962022-10-01 → 2022-12-31dCons.Diluted earnings loss per share IFRS
Equity ratio71.9%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio69.3%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio69.6%at 2022-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-12-31¥172m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-12-31−¥2.1bn
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2023-04-01 → 2023-12-31¥127.8bn
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2023-04-01 → 2023-12-31¥13.9bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2023-04-01 → 2023-12-31¥407.7bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2023-04-01 → 2023-12-31¥92.0bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2023-04-01 → 2023-12-31¥147.3bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2023-04-01 → 2023-12-31¥16.0bn
—segment totalrevenue external2023-04-01 → 2023-12-31¥682.8bn
—segment totalsegment profit2023-04-01 → 2023-12-31¥121.9bn
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-12-31¥186m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31¥479m
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2022-04-01 → 2022-12-31¥113.4bn
jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2022-04-01 → 2022-12-31¥12.9bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2022-04-01 → 2022-12-31¥358.9bn
jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2022-04-01 → 2022-12-31¥83.6bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2022-04-01 → 2022-12-31¥145.5bn
jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2022-04-01 → 2022-12-31¥12.6bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥617.8bn
—segment totalsegment profit2022-04-01 → 2022-12-31¥109.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 653
ItemContextValueUnit
Revenue IFRSCurrentYTDDuration682951000000JPY
Cost of sales IFRSPrior1YTDDuration299646000000JPY
Cost of sales IFRSCurrentYTDDuration328111000000JPY
Gross profit IFRSPrior1YTDDuration318347000000JPY
Gross profit IFRSCurrentYTDDuration354840000000JPY
Selling general and administrative expenses IFRSPrior1YTDDuration224136000000JPY
Selling general and administrative expenses IFRSCurrentYTDDuration251309000000JPY
Other income IFRSPrior1YTDDuration8226000000JPY
Other income IFRSCurrentYTDDuration4320000000JPY
Other expenses IFRSPrior1YTDDuration8922000000JPY
Other expenses IFRSCurrentYTDDuration2332000000JPY
Operating profit loss IFRSPrior1YTDDuration93514000000JPY
Operating profit loss IFRSCurrentYTDDuration105519000000JPY
Finance income IFRSPrior1YTDDuration1915000000JPY
Finance income IFRSCurrentYTDDuration2487000000JPY
Finance costs IFRSPrior1YTDDuration3466000000JPY
Finance costs IFRSCurrentYTDDuration2288000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration136000000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration25000000JPY
Profit loss before tax IFRSPrior1YTDDuration92100000000JPY
Profit loss before tax IFRSCurrentYTDDuration105743000000JPY
Income tax expense IFRSPrior1YTDDuration21920000000JPY
Income tax expense IFRSCurrentYTDDuration25846000000JPY
Profit loss IFRSPrior1YTDDuration70180000000JPY
Profit loss IFRSCurrentYTDDuration79897000000JPY
Profit loss attributable to owners of parent IFRSPrior1YTDDuration70180000000JPY
Profit loss attributable to owners of parent IFRSCurrentYTDDuration79897000000JPY
Profit loss IFRSPrior1YTDDuration70180000000JPY
Profit loss IFRSCurrentYTDDuration79897000000JPY
Basic earnings loss per share IFRSPrior1YTDDuration93.25
Basic earnings loss per share IFRSCurrentYTDDuration107.33
Diluted earnings loss per share IFRSPrior1YTDDuration93.21
Diluted earnings loss per share IFRSCurrentYTDDuration107.29
Revenue IFRSPrior1QuarterDuration214676000000JPY
Revenue IFRSCurrentQuarterDuration239077000000JPY
Cost of sales IFRSPrior1QuarterDuration103322000000JPY
Cost of sales IFRSCurrentQuarterDuration112492000000JPY
Gross profit IFRSPrior1QuarterDuration111354000000JPY
Gross profit IFRSCurrentQuarterDuration126585000000JPY
Selling general and administrative expenses IFRSPrior1QuarterDuration77365000000JPY
Selling general and administrative expenses IFRSCurrentQuarterDuration88054000000JPY
Other income IFRSPrior1QuarterDuration4948000000JPY
Other income IFRSCurrentQuarterDuration1170000000JPY
Other expenses IFRSPrior1QuarterDuration1400000000JPY
Other expenses IFRSCurrentQuarterDuration674000000JPY
Operating profit loss IFRSPrior1QuarterDuration37537000000JPY
Operating profit loss IFRSCurrentQuarterDuration39026000000JPY
Finance income IFRSPrior1QuarterDuration986000000JPY
Finance income IFRSCurrentQuarterDuration1163000000JPY
Finance costs IFRSPrior1QuarterDuration1487000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-12-31pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-12-31pass
statement vs summary · net income attributable to parentconsolidated 2023-10-01/2023-12-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-12-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · revenueconsolidated 2023-04-01/2023-12-31pass
statement vs summary · revenueconsolidated 2023-10-01/2023-12-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass